Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 744

Sort by

Sort Order Select

Journal Articles

The role of CD38 in monocytes during fibrotic progression of myeloproliferative neoplasms

Yiru Yan, Jinqin Liu, Songyang Zhao, Fuhui Li, Lin Yang, Zefeng Xu, Tiejun Qin, Xiaofan Zhu, Wenbin An, Zhongxun Shi, Wenyi Shen, Peihong Zhang, Gang Huang, Raajit K. Rampal, Zhijian Xiao, Bing Li

Blood blood.2025028703.

https://doi.org/10.1182/blood.2025028703

Published: 2025

Includes: Supplemental data

Journal Articles

The glycosaminoglycan oncofetal chondroitin sulfate represents a novel target for antibody drug-conjugate therapy for AML

Blood blood.2024028147.

https://doi.org/10.1182/blood.2024028147

Published: 2025

Includes: Supplemental data

Journal Articles

Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging

Blood (2025) 146 (22): 2681–2695.

https://doi.org/10.1182/blood.2024027692

Published: 2025

Includes: Supplemental data

Journal Articles

Updated results from the Phase 1b/2 study of MK-1045, a novel CD19xCD3 T-cell engager, in adult participants with relapsed or refractory B-cell acute lymphoblastic leukemia

Ying Wang, Qingsong Yin, Jinhai Ren, Hongsheng Zhou, Tiejun Gong, Feng Zhu, Xi Zhang, Qin Wen, Heng Mei, Wei Huang, Zhenghong Chen, Bhargava Kandala, Jingxia Chen, Jianxiang Wang

Blood (2025) 146 (Supplement 1): 647.

https://doi.org/10.1182/blood-2025-647

Published: 2025

Journal Articles

Co-mutation of BCOR and BCORL1 was associated with favorable outcome in the adverse risk patients with Acute Myeloid Leukemia

Shunjie Yu, Zongru Li, Lijuan Hu, Ya-Zhen Qin, Guorui Ruan, Yazhe Wang, Hao Jiang, Feifei Tang, Jinsong JIA, Jing Wang, Qiang Fu, Xiaohui Zhang, Lanping Xu, Yu Wang, Yuqian Sun, Yueyun Lai, Hong-Xia Shi, Xiaojun Huang, Qian Jiang

Blood (2025) 146 (Supplement 1): 3400.

https://doi.org/10.1182/blood-2025-3400

Published: 2025

Journal Articles

Real-world efficacy, safety, and predictive factors for response to glofitamab in Chinese patients with relapsed/refractory aggressive B-cell lymphoma: A multicenter study

Yunfei Lv, Kuang Chen, Chunmei Yang, De Zhou, Juying Wei, Wanzhuo Xie, Gongqiang Wu, Jingcheng Zhang, Qin Pan, Jie Jin, Yanhong Tong, Wenjuan Yu

Blood (2025) 146 (Supplement 1): 7253.

https://doi.org/10.1182/blood-2025-7253

Published: 2025

Journal Articles

Synergistic effects of ASXL1 and BCOR on hematopoiesis and MDS/AML progression

Rongtao Xue, Yuting Qin, Ya Zhou, Xuan Li, Qifa Liu

Blood (2025) 146 (Supplement 1): 1462.

https://doi.org/10.1182/blood-2025-1462

Published: 2025

Journal Articles

Garp/LRRC32 defines the erythroid-megakaryocyte fate decision and enables β-globin program activation

Maria Velegraki, Bradley Blaser, Payton Weltge, Jordan Krull, Maryam Soltani-asl, Emanuele Cocucci, Haitao Wen, Qin Ma, Anjun Ma, Zihai Li

Blood (2025) 146 (Supplement 1): 206.

https://doi.org/10.1182/blood-2025-206

Published: 2025

Journal Articles

Integrated machine learning-based prognostic models for patients with Myelodysplastic Syndromes/neoplasms (MDS)

Xin Wang, Qiujin Shen, Saibing Qi, Xiaowen Gong, Tiejun Qin, Zefeng Xu, Bing Li, Shiqiang Qu, Binhan Jiang, Yue Zhong, Lijuan Pan, Meng Jiao, Qingyan Gao, Robert Gale, Junren Chen, Zhijian Xiao

Blood (2025) 146 (Supplement 1): 7385.

https://doi.org/10.1182/blood-2025-7385

Published: 2025

Journal Articles

Bioflipi scores define distinct immune profiles in follicular lymphoma

Jordan Krull, Qin Ma, Emmanuel Contreras Guzman, Rebecca King, Andrew Feldman, Surendra Dasari, Diwakar Suresh, Jose Villasboas Bisneto, Matthew Maurer, Brian Link, Eric Hsi, Grzegorz Nowakowski, Thomas Habermann, Anne Novak, Melissa Larson, James Cerhan, Stephen Ansell, Patrizia Mondello

Blood (2025) 146 (Supplement 1): 5328.

https://doi.org/10.1182/blood-2025-5328

Published: 2025

Journal Articles

Outcomes in pediatric patients with HSCT-TMA treated with ravulizumab

Michelle Schoettler, David Bueno, Sonali Chaudhury, Jude Fry, Eric Bachman, Min Qin, Elsa Konig, Aviva Krauss, Sarah Lawson, Yoshiyuki Takahashi, Christopher Dvorak, Franco Locatelli

Blood (2025) 146 (Supplement 1): 1052.

https://doi.org/10.1182/blood-2025-1052

Published: 2025

Journal Articles

1,200+ U2AF1 mutations reveal distinct clinicobiological features of the S34/Q157 co-mutation subgroup

Yujiao Jia, Haoxu Wang, Bingqing Huang, Li Qin, Jiao Chang, Ruixue Zhang, Jinqin Liu, Hui Wei, Jianxiang Wang, Jun Shi, Qi Sun, Zhijian Xiao

Blood (2025) 146 (Supplement 1): 3499.

https://doi.org/10.1182/blood-2025-3499

Published: 2025

Journal Articles

Identifying treatment response in AML through a multi-omics classifier of malignant cell states

Yang Song, Linjie Wu, Xiaohuan Qin, Weiqian Dai, Qijun Liao, Liangyu Li, Rui Li, Peide Huang, Jing Zhao, Hui Wei, Sha Hao, Tao Cheng

Blood (2025) 146 (Supplement 1): 3487.

https://doi.org/10.1182/blood-2025-3487

Published: 2025

Journal Articles

Preliminary study results of orelabrutinib in combination with rituximab for treatment-Naïve marginal zone lymphoma: A prospective single-arm clinical trial

Zhifeng Li, Hua Wang, Zhijuan Lin, Li Yu, Shaojie Wu, Na Qin, Jie Zha, Long Liu, Manman Deng, Bing Xu

Blood (2025) 146 (Supplement 1): 3580.

https://doi.org/10.1182/blood-2025-3580

Published: 2025

Journal Articles

Hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in advanced solid tumors: A multicenter, randomized, double-blind, placebo-controlled phase III trial

Blood (2025) 146 (Supplement 1): 1256.

https://doi.org/10.1182/blood-2025-1256

Published: 2025

Journal Articles

Macrophage CD38 overexpression drives primary platelet engraftment failure via paracrine suppression following allogeneic hematopoietic stem cell transplantation

Peng Wang, Jiaqian Qi, Meng Zhou, Wei He, Xiaofei Song, Ming Gao, Pufan Han, Hanyin He, Qin Shi, Han Yue

Blood (2025) 146 (Supplement 1): 4202.

https://doi.org/10.1182/blood-2025-4202

Published: 2025

Journal Articles

Long-term efficacy and safety of ropeginterferon alfa-2b under its hidat regimen for the treatment of polycythemia vera

Blood (2025) 146 (Supplement 1): 2039.

https://doi.org/10.1182/blood-2025-2039

Published: 2025

Journal Articles

USP28 inhibition upregulates CD20 via c-myc suppression and synergizes with anti-CD20 immunotherapy in B-cell lymphomas

Jieyu Xu, Shihui Mao, Pumin Zhang, Hong-Hu Zhu, Jiang-Jiang Qin, Haiyan Yang

Blood (2025) 146 (Supplement 1): 5093.

https://doi.org/10.1182/blood-2025-5093

Published: 2025

Journal Articles

Severe hemolysis flare of refractory warm hemolytic anemia with positive complement component C3d responsive to iptacopan with cyclophosphamide and prednisone

Yawen Zhang, Chengtao Qin, Yuemin Gong, Jianyong Li, Lei Fan, Guangsheng He

Blood (2025) 146 (Supplement 1): 2880.

https://doi.org/10.1182/blood-2025-2880

Published: 2025

Journal Articles

Safety and immunomodulatory effects of siltuximab prophylaxis prior to standard of care CD19 directed chimeric antigen receptor T-cell (CD19.CART) therapy for B-cell lymphomas: Final phase I trial results

Blood (2025) 146 (Supplement 1): 2385.

https://doi.org/10.1182/blood-2025-2385

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The role of CD38 in monocytes during fibrotic progression of myeloproliferative neoplasms

The glycosaminoglycan oncofetal chondroitin sulfate represents a novel target for antibody drug-conjugate therapy for AML

Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging

Updated results from the Phase 1b/2 study of MK-1045, a novel CD19xCD3 T-cell engager, in adult participants with relapsed or refractory B-cell acute lymphoblastic leukemia

Co-mutation of BCOR and BCORL1 was associated with favorable outcome in the adverse risk patients with Acute Myeloid Leukemia

Real-world efficacy, safety, and predictive factors for response to glofitamab in Chinese patients with relapsed/refractory aggressive B-cell lymphoma: A multicenter study

Synergistic effects of ASXL1 and BCOR on hematopoiesis and MDS/AML progression

Garp/LRRC32 defines the erythroid-megakaryocyte fate decision and enables β-globin program activation

Integrated machine learning-based prognostic models for patients with Myelodysplastic Syndromes/neoplasms (MDS)

Bioflipi scores define distinct immune profiles in follicular lymphoma

Outcomes in pediatric patients with HSCT-TMA treated with ravulizumab

1,200+ U2AF1 mutations reveal distinct clinicobiological features of the S34/Q157 co-mutation subgroup

Identifying treatment response in AML through a multi-omics classifier of malignant cell states

Preliminary study results of orelabrutinib in combination with rituximab for treatment-Naïve marginal zone lymphoma: A prospective single-arm clinical trial

Hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in advanced solid tumors: A multicenter, randomized, double-blind, placebo-controlled phase III trial

Macrophage CD38 overexpression drives primary platelet engraftment failure via paracrine suppression following allogeneic hematopoietic stem cell transplantation

Long-term efficacy and safety of ropeginterferon alfa-2b under its hidat regimen for the treatment of polycythemia vera

USP28 inhibition upregulates CD20 via c-myc suppression and synergizes with anti-CD20 immunotherapy in B-cell lymphomas

Severe hemolysis flare of refractory warm hemolytic anemia with positive complement component C3d responsive to iptacopan with cyclophosphamide and prednisone

Safety and immunomodulatory effects of siltuximab prophylaxis prior to standard of care CD19 directed chimeric antigen receptor T-cell (CD19.CART) therapy for B-cell lymphomas: Final phase I trial results

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only